BR112022012230A2 - Variantes de progranulina - Google Patents
Variantes de progranulinaInfo
- Publication number
- BR112022012230A2 BR112022012230A2 BR112022012230A BR112022012230A BR112022012230A2 BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2 BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2
- Authority
- BR
- Brazil
- Prior art keywords
- progranulin
- variants
- proteins
- ftd
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
VARIANTES DE PROGRANULINA. A presente invenção refere-se a variantes de progranulina e proteínas de fusão que compreendem uma variante de progranulina e um polipeptídeo Fc. Métodos de uso de tais proteínas para tratar distúrbios associados à progranulina (por exemplo, uma doença neurodegenerativa, como demência frontotemporal (FTD)) também são fornecidos neste documento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953099P | 2019-12-23 | 2019-12-23 | |
US202063091819P | 2020-10-14 | 2020-10-14 | |
PCT/US2020/066831 WO2021133907A1 (en) | 2019-12-23 | 2020-12-23 | Progranulin variants |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022012230A2 true BR112022012230A2 (pt) | 2022-08-30 |
Family
ID=76437806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022012230A BR112022012230A2 (pt) | 2019-12-23 | 2020-12-23 | Variantes de progranulina |
Country Status (12)
Country | Link |
---|---|
US (4) | US20210188925A1 (pt) |
EP (1) | EP4081536A1 (pt) |
JP (1) | JP2023507846A (pt) |
KR (1) | KR20220130678A (pt) |
CN (1) | CN114981297A (pt) |
AU (1) | AU2020411480B2 (pt) |
BR (1) | BR112022012230A2 (pt) |
CA (1) | CA3165846A1 (pt) |
CO (1) | CO2022008648A2 (pt) |
IL (1) | IL293994A (pt) |
MX (1) | MX2022007486A (pt) |
PE (1) | PE20230036A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof |
CN116121306A (zh) * | 2023-03-27 | 2023-05-16 | 迦进生物医药(上海)有限公司 | 一种human TfR1高表达的稳转细胞株及其构建方法和应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110938A1 (en) | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
WO2002044329A2 (en) | 2000-11-30 | 2002-06-06 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
NZ532027A (en) | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050123962A1 (en) | 2003-10-28 | 2005-06-09 | Agy Therapeutics, Inc. | Regulated nucleic acids in pathogenesis of alzheimer's disease |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
ATE425186T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
DK2037948T3 (en) | 2006-05-30 | 2016-08-01 | Mayo Foundation | Detection and treatment of dementia |
WO2008019187A2 (en) | 2006-05-30 | 2008-02-14 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
PT2029742T (pt) | 2006-06-07 | 2016-09-09 | Genzyme Corp | Terapia genética para esclerose lateral amiotrófica e outros transtornos da medula espinal |
WO2008094687A2 (en) | 2007-01-31 | 2008-08-07 | New York University | Gep, a novel chondrogenic growth factor and target in cartilage disorders |
DE102007033359B4 (de) | 2007-07-16 | 2010-12-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen |
WO2009089635A1 (en) | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
WO2010022175A1 (en) | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
EP2419121B1 (en) | 2009-04-17 | 2018-07-18 | New York University | Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof |
WO2012065248A1 (en) | 2010-11-16 | 2012-05-24 | Kay Denis G | Method for increasing neprilysin expression and activity |
SI2646470T1 (sl) | 2010-11-30 | 2017-05-31 | F. Hoffmann-La Roche Ag | Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade |
CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EA028804B1 (ru) | 2011-03-25 | 2018-01-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
US9809641B2 (en) | 2012-04-23 | 2017-11-07 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
CN104520329A (zh) | 2012-08-29 | 2015-04-15 | 霍夫曼-拉罗奇有限公司 | 血脑屏障穿梭体 |
EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
JP2016501881A (ja) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | 血液脳関門(bbb)を透過する二重特異性結合タンパク質 |
US20140348754A1 (en) | 2013-05-14 | 2014-11-27 | California Institute Of Technology | Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier |
EP2999716A2 (en) | 2013-05-20 | 2016-03-30 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
US10465006B2 (en) | 2013-07-05 | 2019-11-05 | Genmab A/S | Humanized or chimeric CD3 antibodies |
EA202092386A1 (ru) | 2013-07-31 | 2021-04-30 | Эмджен Инк. | Конструкции на основе фактора дифференцировки и роста 15 (gdf15) |
WO2015024931A1 (en) | 2013-08-19 | 2015-02-26 | Moghimi Seyed Moien | Peptidic nanodelivery composition targeting two receptors |
CA2938577A1 (en) | 2014-02-04 | 2015-08-13 | New York University | Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases |
CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
AU2015346045B2 (en) | 2014-11-14 | 2021-08-26 | Ossianix, Inc. | Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use |
US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US11008403B2 (en) | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
PL3221357T3 (pl) | 2014-11-20 | 2020-11-02 | F. Hoffmann-La Roche Ag | Wspólne łańcuchy lekkie i sposoby zastosowania |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
EP3313890A1 (en) | 2015-06-24 | 2018-05-02 | H. Hoffnabb-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
US11390656B2 (en) | 2015-08-04 | 2022-07-19 | New York University | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
AU2016323440B2 (en) | 2015-09-15 | 2023-07-13 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
WO2018013775A2 (en) | 2016-07-14 | 2018-01-18 | Emory University | Granulin compositions and uses related thereto |
IL276191B2 (en) | 2016-12-26 | 2024-02-01 | Japan Chem Res | A new anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
CN111148757A (zh) | 2017-08-10 | 2020-05-12 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
JP2021510162A (ja) | 2018-01-10 | 2021-04-15 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | トランスフェリン受容体結合ポリペプチド及びその使用 |
KR102204521B1 (ko) | 2018-04-17 | 2021-01-20 | 한국생명공학연구원 | Progranulin 단백질을 포함하는 간질환의 예방 또는 치료용 조성물 |
MX2020012518A (es) | 2018-06-18 | 2021-02-16 | Denali Therapeutics Inc | Proteinas de fusion que comprenden progranulina. |
MX2021001711A (es) | 2018-08-16 | 2021-05-27 | Denali Therapeutics Inc | Proteínas biespecíficas modificadas. |
AU2019326545A1 (en) | 2018-08-22 | 2021-03-11 | Denali Therapeutics Inc. | Anti-HER2 polypeptides and methods of use thereof |
JP2022513579A (ja) | 2018-10-16 | 2022-02-09 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン関連障害を処置及びモニタリングするための方法 |
CA3121927A1 (en) | 2018-12-10 | 2020-06-18 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
CA3134538A1 (en) | 2019-04-03 | 2020-10-08 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
KR20220131246A (ko) | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
EP4100419A1 (en) | 2020-02-07 | 2022-12-14 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
CN116420078A (zh) | 2020-10-14 | 2023-07-11 | 戴纳立制药公司 | 用于治疗和监测额颞痴呆的方法 |
IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof |
-
2020
- 2020-12-23 CN CN202080089731.1A patent/CN114981297A/zh active Pending
- 2020-12-23 KR KR1020227022284A patent/KR20220130678A/ko unknown
- 2020-12-23 BR BR112022012230A patent/BR112022012230A2/pt unknown
- 2020-12-23 JP JP2022538728A patent/JP2023507846A/ja active Pending
- 2020-12-23 EP EP20842153.7A patent/EP4081536A1/en active Pending
- 2020-12-23 MX MX2022007486A patent/MX2022007486A/es unknown
- 2020-12-23 IL IL293994A patent/IL293994A/en unknown
- 2020-12-23 AU AU2020411480A patent/AU2020411480B2/en active Active
- 2020-12-23 CA CA3165846A patent/CA3165846A1/en active Pending
- 2020-12-23 PE PE2022001166A patent/PE20230036A1/es unknown
-
2021
- 2021-01-26 US US17/159,038 patent/US20210188925A1/en not_active Abandoned
-
2022
- 2022-03-17 US US17/697,771 patent/US11643446B2/en active Active
- 2022-03-18 US US17/698,456 patent/US20220220172A1/en not_active Abandoned
- 2022-06-21 CO CONC2022/0008648A patent/CO2022008648A2/es unknown
-
2023
- 2023-03-24 US US18/189,413 patent/US20230265137A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114981297A (zh) | 2022-08-30 |
AU2020411480A1 (en) | 2022-06-30 |
AU2020411480B2 (en) | 2023-12-21 |
PE20230036A1 (es) | 2023-01-10 |
CO2022008648A2 (es) | 2022-06-30 |
US20220213155A1 (en) | 2022-07-07 |
MX2022007486A (es) | 2022-06-29 |
US11643446B2 (en) | 2023-05-09 |
KR20220130678A (ko) | 2022-09-27 |
EP4081536A1 (en) | 2022-11-02 |
JP2023507846A (ja) | 2023-02-27 |
US20220220172A1 (en) | 2022-07-14 |
CA3165846A1 (en) | 2021-07-01 |
US20210188925A1 (en) | 2021-06-24 |
US20230265137A1 (en) | 2023-08-24 |
IL293994A (en) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022012230A2 (pt) | Variantes de progranulina | |
CL2020003255A1 (es) | Proteínas de fusión que comprenden progranulina | |
CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
MX2022013526A (es) | Degradadores de proteinas y usos de los mismos. | |
CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
BR112017008157A2 (pt) | polipeptídeos de fgf-21 modificados e usos dos mesmos | |
CL2020000483A1 (es) | Nuevos usos de derivados de piperidinil–indol. | |
BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
MX2020007628A (es) | Composiciones y metodos de uso. | |
BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
ECSP22049014A (es) | Variantes de progranulina | |
CL2020002507A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
CO2022002627A2 (es) | Composiciones biofarmacéuticas y procedimientos conexos | |
CO2022002808A2 (es) | Proteínas de fusión nkg2d y sus usos | |
BR112022014160A2 (pt) | Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau | |
AR115565A1 (es) | Proteínas de fusión que comprenden progranulina | |
EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
EA202091111A1 (ru) | Модуляторы интегрированного стресса | |
AR119587A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos | |
EA202092327A1 (ru) | Варианты lfa3 и их композиции и применение |